Trodelvy has been Approved for ER+/HER2- Patients with Advanced or Metastatic Breast Cancers
XTalks
FEBRUARY 7, 2023
The FDA approval is an important step forward for both women and men living with metastatic breast cancer, especially for those individuals whose tumor is no longer responding to endocrine-based therapies and who are facing a poor prognosis,” said Laura Carfang, executive director, SurvivingBreastCancer.org, in the press release.
Let's personalize your content